Driehaus Capital Management LLC Takes Position in Immunome, Inc. $IMNM

Key Points

• Driehaus Capital Management LLC acquired a new stake in Immunome, Inc., purchasing 610,551 shares valued at approximately $4.11 million, representing about 0.70% ownership.
• Immunome reported better-than-expected earnings, with a quarterly loss of ($0.50) per share, exceeding the consensus estimate of ($0.52), alongside a revenue of $4.02 million.
• Analysts have mixed ratings on Immunome, with several firms adjusting their price targets, and an average target of $22.50, indicating a generally positive outlook.

Driehaus Capital Management LLC purchased a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 610,551 shares of the company's stock, valued at approximately $4,109,000. Driehaus Capital Management LLC owned about 0.70% of Immunome as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Wells Fargo & Company MN lifted its position in shares of Immunome by 45.5% during the 4th quarter. Wells Fargo & Company MN now owns 26,207 shares of the company's stock valued at $278,000 after acquiring an additional 8,190 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Immunome during the fourth quarter valued at $274,000. MetLife Investment Management LLC boosted its position in shares of Immunome by 17.7% in the 4th quarter. MetLife Investment Management LLC now owns 35,619 shares of the company's stock valued at $378,000 after purchasing an additional 5,354 shares during the period. Tower Research Capital LLC TRC increased its stake in Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Immunome during the 4th quarter worth about $95,000. Institutional investors own 44.58% of the company's stock.

Immunome Trading Down 5.0%

NASDAQ IMNM traded down $0.51 during trading on Thursday, hitting $9.74. 530,087 shares of the company traded hands, compared to its average volume of 985,849. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.73. The business has a fifty day simple moving average of $9.83 and a 200 day simple moving average of $8.85. The company has a market capitalization of $847.82 million, a P/E ratio of -3.16 and a beta of 1.92.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.02. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%.The company had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. Equities research analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IMNM shares. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. JPMorgan Chase & Co. decreased their price objective on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Evercore ISI assumed coverage on shares of Immunome in a research note on Friday, August 22nd. They set an "outperform" rating and a $18.00 target price on the stock. Wedbush restated an "outperform" rating and issued a $21.00 target price on shares of Immunome in a report on Thursday, August 7th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $22.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.